Scarica l'app Stockscreener
285.64
0.16%
0.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$285.19
Aprire:
$284.58
Volume 24 ore:
4.60M
Relative Volume:
0.83
Capitalizzazione di mercato:
$504.76B
Reddito:
$62.82B
Utile/perdita netta:
$3.60B
Rapporto P/E:
140.89
EPS:
2.0274
Flusso di cassa netto:
$19.98B
1 W Prestazione:
+0.08%
1M Prestazione:
+7.76%
6M Prestazione:
+42.14%
1 anno Prestazione:
+25.14%
Intervallo 1D:
$282.30
$286.76
Intervallo di 1 settimana:
$278.01
$290.98
Portata 52W:
$190.75
$291.40
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
285.64 | 504.76B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,273.46 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.81 | 635.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
145.27 | 358.41B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.24B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-08-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2026-04-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2026-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-08 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-10 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-04 | Downgrade | DZ Bank | Buy → Hold |
| 2025-10-14 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF - The Motley Fool
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research
Abbvie, Vertex lead $32B September biopharma M&A surge - BioWorld News
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
AbbVie stock: Cantor lifts target for AbbVie stock from USD 285 to USD 290 - ad-hoc-news.de
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
AbbVie Inc. (ABBV80.BK) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts - Yahoo Finance
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - The Globe and Mail
AbbVie stock: At 1.84 percent below its 52-week high, AbbVie stock trades at EUR 255.05 - ad-hoc-news.de
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying? - Yahoo Finance
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
AbbVie ABBV-466 Achieves 40.5% Crohn's Remission - grafa.com
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - TradingView
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - TradingView
AbbVie (ABBV) Reports Promising Phase 2a Data for ABBV-466 in Cr - GuruFocus
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It - The Motley Fool
AbbVie (ABBV) to Showcase Expanded Solid Tumor Research at ESMO Congress - GuruFocus
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors? - Yahoo Finance
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle - The Motley Fool
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - Yahoo Finance
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - The Motley Fool
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
AbbVie vs. Merck: Which Pharma Stock Offers Better Value? - Yahoo Finance
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? - Yahoo Finance
5 Stock Ideas for Your Short List - TradingView
5 Stock Ideas for Your Short List - Zacks Investment Research
Scotiabank lifts target for AbbVie stock from USD 280.00 to USD 320.00 - ad-hoc-news.de
AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs - BigGo Finance
Form 4 AbbVie Inc For: 16 October By Investing.com - Investing.com Nigeria
AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands - Yahoo Finance
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
Abbvie Inc. Announces Appointment of John M. Carethers as Director and Member of Public Policy and Sustainability Committee - www.marketscreener.com
The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF - The Motley Fool
Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot - Bloomberg Law News
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
AbbVie’s Q3 2026 Earnings: What to Expect - Barchart.com
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? - Zacks Investment Research
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Abbvie Inc Azioni (ABBV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Aug 14 '26 |
Sale |
250.00 |
32,710 |
8,177,500 |
74,430 |
| NICHOLAS DONOGHOE | Officer |
Aug 14 '26 |
Proposed Sale |
250.00 |
32,710 |
8,177,500 |
0 |
| ROBERT J ALPERN | Director |
May 26 '26 |
Proposed Sale |
214.00 |
13,000 |
2,781,991 |
0 |
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
| David R. Purdue | Officer |
Mar 04 '26 |
Proposed Sale |
233.56 |
5,230 |
1,221,519 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
234.39 |
18,668 |
4,375,549 |
4,619 |
| PERRY C SIATIS | Officer |
Mar 02 '26 |
Proposed Sale |
234.39 |
18,668 |
4,375,585 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Option Exercise |
172.62 |
22,381 |
3,863,458 |
60,518 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Sale |
230.00 |
22,381 |
5,147,630 |
38,137 |
| PERRY C SIATIS | Officer |
Feb 25 '26 |
Proposed Sale |
230.00 |
22,381 |
5,147,630 |
0 |
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):